Ascendis Pharma AS Cash Flow Conversion Efficiency
Ascendis Pharma AS cash flow conversion efficiency. Based on the latest financial reports, Ascendis Pharma AS (A71) has a cash flow conversion efficiency ratio of -0.016x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-7.72 Million ≈ $-9.03 Million USD) by net assets (€487.97 Million ≈ $570.49 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Ascendis Pharma AS (2016–2025)
Cash flow conversion efficiency of Ascendis Pharma AS from 2016 to 2025. This chart illustrates how Ascendis Pharma AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Ascendis Pharma AS (A71) stock price for real-time trading data and today's change.
Ascendis Pharma AS Cash Flow Conversion Ratio Explained
Ascendis Pharma AS cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Ascendis Pharma AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ascendis Pharma AS ranked by their cash flow conversion efficiency. Also see market cap of Ascendis Pharma AS for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Phison Electronics
TWO:8299
|
0.036x |
|
China Railway Group Limited
SHG:601390
|
0.013x |
|
Smith & Nephew SNATS Inc
NYSE:SNN
|
0.168x |
|
Polycab India Limited
NSE:POLYCAB
|
-0.010x |
|
AB SKF (publ)
ST:SKF-B
|
0.034x |
|
Lifco AB (publ)
ST:LIFCO-B
|
0.054x |
|
Penumbra Inc
NYSE:PEN
|
0.030x |
|
VERBUND AG ADR 1/5/O.N.
F:OEW
|
0.023x |
Annual Cash Flow Conversion Efficiency for Ascendis Pharma AS (2016–2025)
The table below shows the annual cash flow conversion efficiency of Ascendis Pharma AS from 2016 to 2025. Review Ascendis Pharma AS (A71) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €-162.82 Million ≈ $-190.35 Million |
€53.90 Million ≈ $63.01 Million |
-0.331x | -111.43% |
| 2024-12-31 | €-105.71 Million ≈ $-123.58 Million |
€-306.20 Million ≈ $-357.98 Million |
2.897x | -9.70% |
| 2023-12-31 | €-145.70 Million ≈ $-170.34 Million |
€-467.36 Million ≈ $-546.39 Million |
3.208x | +270.42% |
| 2022-12-31 | €263.35 Million ≈ $307.88 Million |
€-495.70 Million ≈ $-579.52 Million |
-1.882x | -298.24% |
| 2021-12-31 | €883.63 Million ≈ $1.03 Billion |
€-417.65 Million ≈ $-488.28 Million |
-0.473x | -45.98% |
| 2020-12-31 | €838.71 Million ≈ $980.54 Million |
€-271.55 Million ≈ $-317.47 Million |
-0.324x | -9.88% |
| 2019-12-31 | €597.11 Million ≈ $698.09 Million |
€-175.94 Million ≈ $-205.69 Million |
-0.295x | +40.55% |
| 2018-12-31 | €280.05 Million ≈ $327.41 Million |
€-138.80 Million ≈ $-162.27 Million |
-0.496x | +2.43% |
| 2017-12-31 | €187.21 Million ≈ $218.87 Million |
€-95.10 Million ≈ $-111.18 Million |
-0.508x | -49.08% |
| 2016-12-31 | €176.61 Million ≈ $206.48 Million |
€-60.18 Million ≈ $-70.36 Million |
-0.341x | -- |
About Ascendis Pharma AS
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is a… Read more